\
&
Contact us
This was 1 year ago
LocationOn site (Skopje, North Macedonia) or online
This conference, organised by Science|Business, will highlight the opportunities to strengthen the European Research Area and explore how entities, researchers, and innovators can benefit most from the EU's research framework based on excellence and respect for differences. It will give a specific focus on the maintenance, construction, and integration of Research Infrastructures (RI) into the broader EU RI fleet, aiming to create a unified and cohesive European research environment.
Panel discussions will explore national differences in research and innovation policy and practices across Southeast Europe, highlighting successful strategies and identifying areas for improvement. Another major focus in the conference will be how the EU and Southeast European countries can work together to address the 'brain drain' by discussing strategies to make the region more attractive to researchers.
The conference will provide a forum for discussing policies and best practices and will be an excellent opportunity to engage with key decision-makers from the EU and Southeast European research and innovation communities.
More information on this event and programme can be found here. This event can be attended in person or online.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.